Yasutaka Shinoda

Yasutaka Shinoda

Auto-generated profile, based on publicly available information

Yasutaka Shinoda

Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
YSYasutaka Shinoda
Yasutaka Shinoda
TTTakamasa Takahashi
Takamasa Takahashi
HSHiroaki Shikano
Hiroaki Shikano
EUEiseki Usami
Eiseki Usami

20 May 2016 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
YSYasutaka Shinoda
Yasutaka Shinoda
MKMichio Kimura
Michio Kimura
EUEiseki Usami
Eiseki Usami
HAHiroki Asano
Hiroki Asano
TYTomoaki Yoshimura
Tomoaki Yoshimura
Paclitaxel is mainly inactivated in vivo by cytochrome P5402C8 (CYP2C8). In recent years, the clopidogrel metabolite has been reported to potently inhibit CYP2C8. However, clinical information regarding the interaction between these two drugs is limited. To the best of our knowledge, this is the first retrospective study investigating the potential for the drug interaction between paclitaxel and clopidogrel. A total of 8 cases in which clopidogrel and paclitaxel were used in combination were examined. The incidence of adverse events and discontinuation rate in these cases were assessed. Neutrophil counts were compared in patients prior and subsequent to the combined administration of clopidogrel and paclitaxel. Grade 3 neutropenia occurred in all cases of combination therapy and grade 4 occurred in 7 cases (88%). In addition, 4 cases (50%) showed febrile neutropenia. Four cases (50%) involved a severe adverse event requiring discontinuation of drug administration. In 1 case involving 6 courses of paclitaxel and nedaplatin therapy prior and subsequent to clopidogrel, there was a significant reduction in the average neutrophil count after 8 days of combination treatment (1,240±395 counts/mm3 without clopidogrel; 370±148 counts/mm3 with clopidogrel; mean ± standard deviation, P<0.01). Drug interactions during co-administration of clopidogrel and paclitaxel may cause severe neutropenia. To avoid these interactions, alternative medications should be considered. If these two drugs are used in combination, it may be necessary to monitor for adverse events more carefully.

1 July 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RSRie Shinoda
Rie Shinoda
YSYasutaka Shinoda
Yasutaka Shinoda
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
THTatsuya Hirose
Tatsuya Hirose
TYTomoaki Yoshimura
Tomoaki Yoshimura

1 February 2016 in Die Pharmazie
Verified
Journal Article
Closed access
YSY. Shinoda
Y. Shinoda
TMT. Matsuoka
T. Matsuoka
TMT. Mori
T. Mori
SYS. Yoshida
S. Yoshida
KOK. Ohashi
K. Ohashi
TST. Sugiyama
T. Sugiyama
Inappropriate antimicrobial treatment could adversely affect the recovery of patients with aspiration pneumonia. We attempted to identify inappropriate antibacterial treatment and to determine the standard use of anti-methicillin-resistant Staphylococcus aureus (MRSA) drugs in aspiration pneumonia patients with MRSA-positive in sputum. Aspiration pneumonia patients with MRSA-positive sputum treated between January 2013 and May 2013 were included in this study to determine the risk factors for death during hospitalization. The relationship between anti-MRSA medicine use and death during hospitalization was also investigated. More than 107 MRSA colony-forming units in sputum culture, creatinine clearance of less than 30 mL/min, and quinolone use were found to be risk factors for death during hospitalization. The death rate during hospitalization was significantly lower in cases a Geckler classification of 4 or 5 when anti-MRSA treatment was initiated soon after the culture was obtained. Therefore, we concluded that the use of quinolones as antibacterial treatment in aspiration pneumonia patients with MRSA-positive sputum should be avoided and that anti-MRSA treatment should be started in cases with good quality sputum cultures.

1 February 2022 in American Journal of Infection Control
Verified
Journal Article
Closed access
YSYasutaka Shinoda
Yasutaka Shinoda
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
KAKaori Arai
Kaori Arai
NHNao Hotta
Nao Hotta
TYTomoaki Yoshimura
Tomoaki Yoshimura

28 November 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
YSYasutaka Shinoda
Yasutaka Shinoda
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
KAKaori Arai
Kaori Arai
NHNao Hotta
Nao Hotta
EUEiseki Usami
Eiseki Usami
Background: Aminoglycosides are crucial for treating multidrug-resistant gram-negative infections and endocarditis. However, aminoglycosides are associated with significant risks of nephrotoxicity, necessitating careful dose selection and therapeutic drug monitoring. Therapeutic drug monitoring is essential for minimizing risk; however, few institutions routinely perform it. This study aimed to assess the impact of a pharmacist-driven therapeutic drug monitoring intervention on aminoglycoside usage trends and clinical outcomes. Methods: This retrospective cohort study included 263 patients treated with aminoglycosides between 2014 and 2023. A pharmacist-led therapeutic drug monitoring intervention began in 2017, focusing on monitoring renal function, documenting patient weight, and closely managing aminoglycoside concentrations. Trends in aminoglycoside use and renal outcomes were analyzed. Results: Over the study period, appropriate use of aminoglycosides at the time of initial prescription increased from 49 to 82% (P < 0.01). Pharmacist dosing design at initial prescription increased significantly from 21% pre-intervention to 60% post-intervention (P < 0.01). The proportion of pharmacist intervention in initial dosing design increased over time. The proportion of patients with measured aminoglycoside blood concentrations significantly increased from 53% pre-intervention to 72% post-intervention (P < 0.01). The proportion of patients who were able to manage target blood concentrations from the initial aminoglycoside dose without dose adjustments increased from 31% pre-intervention to 42% post-intervention, although the results were not significantly different (P = 0.07). The incidence rate of renal impairment remained similar (11% vs. 12%; P = 0.85), although the annual average number of cases decreased from 4.3 before the intervention to 2.5 after. Similarly, there were no significant differences in clinical efficacy before and after the intervention (65% vs. 71%; P = 0.35). Furthermore, aminoglycoside stewardship led to a 56% cost saving. Conclusions: Pharmacist-led aminoglycoside stewardship significantly improved the appropriate use of aminoglycosides and decreased the associated costs. Thus, pharmacist involvement is essential for the proper use of aminoglycosides. However, many patients required aminoglycoside dose reductions despite the pharmacist’s guideline-based dosing design. Therefore, further accumulation of information on the management of aminoglycoside blood concentration may be necessary for the revision of these guidelines.